Skip to main content

Cancer Cell Metabolism and Tumor Microenvironment Remodel

50kviews
Editorial: Cancer cell metabolism and tumor microenvironment remodel
Editorial10 August 2026
Editorial: Cancer cell metabolism and tumor microenvironment remodel

Metabolic reprogramming that supports proliferative energetics is an established hallmark of cancer. Yet, it is becoming evident that metabolic reprogramming extends beyond energetics and that metabolites serve as bioactive molecules that exert biophysical properties to promote cancer cell progression and that aid in shaping of the tumor microenvironment (TME). Moreover, these metabolic alterations are not limited to cancer cells, but also reflect contributions of other cell types within TME, including microbes. In this context, metabolites should be viewed not merely as fuels or metabolic byproducts, but as functional mediators that influence signaling, epigenetic regulation, organelle homeostasis, immune cell fate, and therapeutic response. Here, we shed light on these metabolic adaptations and how this knowledge translates into novel strategies for cancer treatment.

Metabolic adaptations, primarily characterized in the context of oxidative phosphorylation and aerobic glycolysis, optimize biosynthesis of energy sources and cellular building blocks to support cell proliferation. Paracrine secretion of lactate, certain amino acids, e.g. glutamine, and lipids, e.g. fatty acids, have also been shown to be utilized as alternative sources of 'fuel' [1].While less characterized, emerging evidence also implicates biophysical properties of metabolites for maintenance and clearance of intracellular organelles, particularly mitochondria, to support cancer survival and proliferation. To this end, using spatial metabolite imaging, Chen and colleagues identified long-chain hydroxylated sulfatides to be selectively enriched in neoplastic epithelium of intraductal papillary mucinous neoplasms (IPMN), established precursor lesions to pancreatic ductal adenocarcinoma (PDAC) [2]. Through spatial transcriptomics, authors further showed cognate transcripts involved in sulfatide metabolism, including ceramide galactosyltransferase (also known as UGT8) and galactose-3-O-sulfotransferase 1 (GAL3ST1), to co-localize with areas of sulfatide enrichment. Mechanistically, sulfatide biosynthesis was linked to maintenance of mitochondrial morphology and function. Genetic or pharmacological suppression of UGT8 resulted in mitochondrial enlargement, loss of mitochondrial respiration, and increased susceptibility to intrinsic apoptosis [2]. These findings insinuate a role a biophysical role of sulfatide in maintaining cancer-cell associated mitochondrial function, which may have broad relevance to other cancer types [3][4][5].Vykoukal and colleagues reported that enhanced scavenging of sphingomyelin by cancer cells, which they detailed in the context of triple negative breast cancer, is a ready source of ceramides for glycosphingolipid biosynthesis that supports extracellular vesicle (EV)-mediated clearance of damaged mitochondria as an alternative complementary mechanism to mitophagy. Glucosylceramide synthase (UGCG) was identified as a key mediator of this onco-metabolic process. Small molecule targeting of UGCG via repurposing of eliglustat resulted in ceramide-mediated mitophagy and subsequent cell death in vitro and markedly attenuated tumor development in vivo [6]. Similar findings have also been reported in prostate cancer [7]. These findings provide compelling evidence linking glycosphingolipid metabolism to regulation of mitochondrial dynamics, with potential therapeutic benefit.

Metabolites within the TME may emerge from cancer cells, stromal and immune cells with considerable work to-date describing the biological impact of metabolic byproducts such as lactate, kynurenine, and adenosine on the TME [8][9][10][11][12]. Additional lipidassociated metabolites such as acetate, phosphoethanolamine (pEtn), and bioactive aldehydes within the TME have since been identified to promote cancer progression.Specifically, Murthy and colleagues demonstrated that cancer-associated fibroblasts (CAFs) release acetate to fuel pancreatic cancer (PDAC) survival under metabolic stress through acetyl-CoA synthetase short-chain family member 2 (ACSS2)mediated acetylation of SP1 and spermidine/spermine N 1 -acetyltransferase 1 (SAT1)drive upregulation of polyamine metabolism [13]. Genetic or pharmacological inhibition of the ACSS2-SP1-SAT1 axis attenuated tumor development in cell line-and patientderived xenograft models of PDAC [13]. CAF-derived lactate has also been shown to induce lactylation of the spliceosome component SNRPA at Lys123 (K123), resulting in enhanced chromatin binding and androgen receptor splicing in prostate cancer cells that drives resistance to androgen-deprivation therapy (ADT) [14]. Targeting of the lactate transporter via monocarboxylate transport inhibitors effectively restored sensitivity to ADT [14]. Wang et al. identified phosphoethanolamine (pEtn), an intermediate in phospholipid biosynthesis, to be highly elevated in tumor interstitial fluid and increased accumulation of this onco-metabolite was found to suppress CD8⁺ T-cell effector function and increase expression of inhibitory molecules PD-1, Tim-3, and Lag3 [15]. Mechanistically, pEtn promoted CD8⁺ T-cell dysfunction by limiting diacylglyceroldependent TCR signaling [15]. Using a B16-Pcyt2 overexpression model of melanoma, authors further found that reduction of intratumoral pEtn levels improved T-cell function and tumor control compared to B16-empty vector control-tumor bearing mice, supporting the notion that pEtn is an immunosuppressive onco-metabolite [15].Beyond pEtn, lipid byproducts such as the reactive aldehyde acrolein also contribute to an immunosuppressive TME. Haku and colleagues showed that loss of HADHA and SLC25A20 impairs fatty acid oxidation, causing mitochondrial stress, acrolein accumulation, AKT-mTOR activation, GLUT1 upregulation, and T cell exhaustion. Blocking acrolein accumulation with lipid peroxidation inhibitors or Nbenzylhydroxylamine enhanced PD-1 blockade efficacy in MC38 colon adenocarcinoma models [16].

Seminal work by others have demonstrated that alterations in microbial metabolism directly influence tumor behavior and response to therapy, and it is now acknowledged that the symbiotic relationship between mammalian organisms and 'microbiomes' is a new hallmark of cancer [17]. Bachem et al. showed that microbiotaderived butyrate enhances anti-melanoma immunity by preserving tumor-specific CD8⁺ T cell stemness in tumor-draining lymph nodes. Mechanistically, butyrate acts directly on CD8⁺ T cells and promotes a FOXO1-dependent transcriptional program, thereby increasing CD127⁺ stem-like CD8⁺ T cells while limiting terminal exhaustion. These findings suggest that microbial metabolites can enhance anti-tumor T cell immunity and improve immune checkpoint blockade efficacy [18]. Jia et al. demonstrated that Lactobacillus johnsonii enhances immune checkpoint blockade efficacy across cancer types by promoting stem-like CD8⁺ T cell immunity. At the molecular level, L. johnsonii cooperates with Clostridium sporogenes to generate indole-3-propionic acid, which increases H3K27 acetylation at the Tcf7 super-enhancer and activates progenitor exhausted CD8⁺ T cells. These findings identify a microbiota-derived epigenetic metabolite axis that preserves T cell stemness [19]. This Research Topic highlights metabolic reprogramming as a key driver of tumor microenvironment remodeling and cancer progression. Metabolites derived from tumor, stromal, immune, and microbial cells reshape nutrient availability, immune function while creating exploitable metabolic vulnerabilities. Targeting these metabolic dependencies may therefore provide new therapeutic opportunities, especially when integrated with immune checkpoint inhibitors or other existing anticancer therapies to enhance treatment efficacy.

1,252 views

REVIEW
8 October 2025
Epigenetic and metabolic reprogramming via nanotechnology: a synergistic approach to cancer vaccination in lung tumors
Min Xu, 7 more and Ran Cui
Epigenetic and metabolic reprogramming via nanotechnology: a synergistic approach to cancer vaccination in lung tumors
Cancer vaccines represent a promising therapeutic modality in immuno-oncology, yet their efficacy is severely constrained within the immunosuppressive microenvironment of lung tumors. Metabolic reprogramming and epigenetic dysregulation are now understood as critical, interconnected determinants that orchestrate tumor microenvironment (TME) immunosuppression and fundamentally shape anti-tumor immune responses. This review comprehensively examines the mechanistic interplay between metabolic reprogramming and epigenetic regulation, and how nanoplatform technologies can be engineered to modulate these axes to augment cancer vaccine efficacy. We analyze advanced nano-delivery system design strategies, the synergistic effects of combining metabolic intervention with epigenetic modification, and their application in overcoming the formidable barriers of the lung TME. By integrating recent advances in nanotechnology, epigenetics, and tumor immunometabolism, we provide critical insights into the development of next-generation cancer vaccines. Furthermore, we propose a novel conceptual framework—The Epi-Met-Immune Synergistic Network—to dissect these interactions and identify key nodes for rational therapeutic intervention, aiming to enhance and sustain durable anti-tumor immunity.

4,300 views

6 citations

ORIGINAL RESEARCH
5 December 2025
Emodin inhibits colon cancer tumor growth by suppressing tumor cell glycolysis through inhibition of NAT10-mediated PGK1 ac4C modification
Zhuoxin Wei, 1 more and Weimin Zhang

2,137 views

4 citations

Tumor-derived SEMA7A regulates fatty acid oxidation in the tumor-associated macrophages to promote the progression of non-small cell lung cancer
ORIGINAL RESEARCH
11 September 2025
Tumor-derived SEMA7A regulates fatty acid oxidation in the tumor-associated macrophages to promote the progression of non-small cell lung cancer
Jia Wang, 4 more and Beixing Liu
Non-small cell lung cancer (NSCLC) is an aggressive cancer with a poor prognosis. Despite the success of therapies for NSCLC, more investigations of new biomarkers for patient selection are urgently needed. Semaphorin 7A (SEMA7A), a soluble tumor-derived molecule, can modulate the proliferation, invasion and angiogenesis of multiple types of cancers. However, whether SEMA7A contributes to the progression of NSCLC is still unknown. In this study, by using bioinformatics analysis and an experimental murine tumor model, we found that the expression levels of SEMA7A were elevated in the human NSCLC and positively correlated with the poor prognosis. Knockdown of SEMA7A in cancer cells may suppress NSCLC progression, in parallel with a diminished M2 polarization in the tumor microenvironment (TME). In fact, SEMA7A may increase the polarization of tumor-associated macrophages (TAMs) toward the M2 phenotype in an ITGB1-dependent manner. Fatty acid oxidation in macrophages seems to be essential for the ability of SEMA7A to promote M2 polarization. Blockade of fatty acid oxidation may reverse the immunosuppressive phenotype of TAMs and the outcomes of NSCLC. Our findings provide experimental evidence that SEMA7A may act as a regulatory factor for macrophage lipid metabolism, which influences the polarization status of TAMs.

3,688 views

9 citations

METHODS
15 September 2025
Construction of a novel prognostic model for gastric cancer based on pharmacokinetics-related genes and comprehensive prognostic analysis
Yu Zhang, 5 more and He Huang

2,911 views

1 citations

REVIEW
25 July 2025
Metabolism and epigenetics in cancer: toward personalized treatment
Xiaoman Zhang, 4 more and Guangzhen Wu

5,301 views

13 citations

REVIEW
6 August 2025
GOT2: a moonlighting enzyme at the crossroads of cancer metabolism and theranostics
Junxi Hu, 5 more and Yusheng Shu

5,458 views

7 citations

ORIGINAL RESEARCH
16 July 2025
Characterization of lactylation modification subtypes and the promoting role of CCL20 in hepatocellular carcinoma progression
Li-Hong Wu, 6 more and Fei Tian
Characterization of lactylation modification subtypes and the promoting role of CCL20 in hepatocellular carcinoma progression
BackgroundHepatocellular carcinoma (HCC) is a highly aggressive and deadly malignancy. Early identification of prognostic risk factors is crucial for guiding clinical management and improving patient outcomes. Lactylation modification plays a pivotal role in tumorigenesis, yet the regulatory mechanisms and prognostic significance of lactylation-related genes in HCC remain insufficiently understood.MethodsThis study screened for prognostically significant lactylation modification-related genes based on their expression levels, integrated with DFS, PFS, and OS data. HCC patients were stratified into three distinct lactylation modification subtypes (C1, C2, C3) using the NMF algorithm. Differentially expressed genes across the three subtypes were identified through an intersection analysis. A lactylation modification-related prognostic model was subsequently constructed using LASSO-Cox and multivariate Cox regression analyses. The CIBERSORT algorithm was utilized to analyze immune cell infiltration. Functional validation of the lactylation-related gene CCL20 in HCC was conducted through in vitro experiments using HCC cell lines.ResultsWe identified three distinct lactylation modification patterns, with higher lactylation modification levels correlating with worse prognosis in HCC. A six-gene lactylation modification-based prognostic model (LRPS), including FAM83D, ENO1, PFN2, LCAT, PTGR1, and CCL20, was constructed and validated. Overall survival was markedly reduced in the high LRPS group relative to the low LRPS group. The high LRPS group also showed a significantly higher frequency of TP53 mutations. Correlation analysis of immune cell infiltration revealed a significant association between LRPS and the infiltration abundance of M0 macrophages, Tregs, and neutrophils, suggesting that lactylation modification may influence the tumor immune microenvironment. Overexpression of CCL20 in HCC cells significantly enhanced their proliferative and migratory capacities, indicating a key role for CCL20 in HCC progression.ConclusionThis study established a lactylation modification-based prognostic model that accurately forecasts outcomes in HCC patients. This risk score showed a significant correlation with glucose metabolism and reflected immune cell infiltration patterns. The core model gene, CCL20, promotes HCC cell proliferation and migration, supporting its potential as a valuable prognostic biomarker and a therapeutic target for HCC.

4,361 views

4 citations

ORIGINAL RESEARCH
10 March 2025
Wnt/β-catenin pathway activation is associated with glucocorticoid secretion in adrenocortical carcinoma, but not directly with immune cell infiltration
Tanja Maier, 11 more and Matthias Kroiss

3,586 views

8 citations